Antiviral resistance monitoring capability and capacity for SARS-CoV-2 and influenza within the EU/EEA
Surveillance and monitoring
This report presents the results from a survey among 30 EU/EEA countries.
Executive Summary
- More than half of EU/EEA countries perform antiviral resistance testing for influenza, and three countries perform antiviral resistance testing for SARS-CoV-2.
- Most of the countries are interested in extending their antiviral resistance testing, either to influenza or SARS-CoV-2 or to both.
- Antiviral resistance monitoring of new virus variants could improve the appropriate clinical use of antiviral drugs.
- For SARS-CoV-2, most countries rely on genotypic analyses for antiviral resistance testing, with very few countries performing both genotypic and phenotypic analyses.
- For influenza, most countries perform both genotypic and phenotypic analyses.
- Whole Genome Sequencing is becoming the most commonly used approach for antiviral resistance analysis, allowing rapid identification, monitoring and assessment of mutations creating antiviral resistant variants.
Publication file
Antiviral resistance monitoring capability and capacity for SARS-CoV-2 and influenza within the EU/EEA
English (387.8 KB - PDF)
Share this page